2021 Fiscal Year Final Research Report
Roles of CD69-Myl9 system for vasculitis in Kawasaki disease
| Project/Area Number |
19K08330
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
|---|
| Research Institution | Chiba University (2021)
Tokyo Women's Medical University (2019-2020) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小林 弘信 千葉大学, 医学部附属病院, 医員 (50729019)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 川崎病 / 血小板 / 血管炎 / 小児 |
|---|
| Outline of Final Research Achievements |
In Kawasaki disease (KD), which is a disease of unknown cause that is common in Japanese children, coronary aneurysm is the most important complication. In KD patients, platelets in the blood are activated, and Myl9 derived from them is elevated compared to other febrile diseases, and inflammatory cells carrying the Myl9 receptor CD69 are recruited in the blood. Furthermore, in the heart tissue of a child who died of KD, Myl9 was expressed in blood clots and blood vessel walls, and its location changed with the course of the disease.In mouse model of coronary arteritis, Myl9 was first expressed in the coronary artery tissue, followed by inflammatory cell infiltration.These data suggest a part of the mechanism of vascular inflammation that causes aneurysm.
|
| Free Research Field |
小児科学
|
| Academic Significance and Societal Importance of the Research Achievements |
全身性炎症性疾患の川崎病において、動脈瘤を起こす血管炎症の機序の一部を解明した。川崎病の最大の合併症である冠動脈瘤を予防する特異的な治療の開発につながる成果である。現在の標準治療である血漿分画製剤にかわる治療薬の開発ができれは、子ども達の健康に寄与する。
|
